Generic Rapaflo Availability
RAPAFLO (silodosin - capsule;oral)
Has a generic version of Rapaflo been approved?
No. There is currently no therapeutically equivalent version of Rapaflo available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rapaflo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
1,5,7-trisubstituted indoline compounds and salts thereof
Issued: February 7, 1995
Inventor(s): Kitazawa; Makio & Ban; Masaaki & Okazaki; Kosuke & Ozawa; Motoyasu & Yazaki; Toshikazu & Yamagishi; Ryoichi
Assignee(s): Kissei Pharmaceutical Co., Ltd.
Indoline compounds represented by the formula: ##STR1## wherein R represents a saturated or unsaturated aliphatic acyl group which may have one or more halogen atoms, a hydroxy group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, a cycloalkyl group or an aryl group as substituents; a hydroxyalkyl group; an aliphatic acyloxyalkyl group; a lower alkyl group having a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an aryl substituted lower alkoxycarbonyl group, a carbamoyl group, a mono- or dialkyl substituted carbamoyl group or a cyano group as substituents; an aromatic acyl group which may have one or more halogen atoms as substituents; a furoyl group or a pyridylcarbonyl group; R.sup.1 represents a lower alkyl group which may have one or more halogen atoms or an aryl group as substituents; and pharmaceutically acceptable salts thereof, exhibit a selective suppressive action on urethral contractions, and thus are useful as therapeutic agents for the treatment of dysuria with less hypotension including postural hypotension.Patent expiration dates:
- December 1, 2018✓✓
- December 1, 2018
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- October 8, 2013 - NEW CHEMICAL ENTITY
- Rapaflo Consumer Information (Drugs.com)
- Rapaflo Consumer Information (Wolters Kluwer)
- Rapaflo Consumer Information (Cerner Multum)
- Rapaflo Advanced Consumer Information (Micromedex)
- Rapaflo AHFS DI Monographs (ASHP)
- Silodosin Consumer Information (Wolters Kluwer)
- Silodosin Consumer Information (Cerner Multum)
- Silodosin Advanced Consumer Information (Micromedex)
- Silodosin AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|